InflaRx N.V. (IFRX) Reports Positive Data form Third Cohort of Phase IIa Open-Label Study with Vilobelimab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to InflaRx N.V. (IFRX) Reports Positive Data form Third Cohort of Phase IIa Open-Label Study with Vilobelimab

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

October 27, 2021 7:30 AM EDT

6 out of 7 patients (85.7%) showed clinical remission (PGA score 1) and closure of target ulcer in the highest dose cohortTreatment was well tolerated; no dose-related adverse events observedFinal post treatment observational data will be available in the first half of 2022InflaRx to host conference call today at 8:30 am EDT / 2:30 pm CEST

JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces positive data from the third cohort of patients in the Phase IIa... More